Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics Inc.

Fulcrum Therapeutics (($FULC)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Fulcrum The...

Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential

Fulcrum Therapeutics ( ($FULC) ) has released its Q3 earnings. Here is a breakdown of the information Fulcrum Therapeutics presented to its investo...

Fulcrum Therapeutics Reports Q3 2025 Progress and Financials

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Quoin Pharmaceuticals (QNRX – Research Report) and F...

Analysts Are Bullish on Top Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Fulcrum Therapeutics (FULC)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Fulcrum Therapeutics today and set a price target of $15.00. The company’s shares op...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FULC	$11.29	+2.08%	431.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FULC	$11.29	+2.1%	431.99K
3
4
5
6

FULC

FULC

No Data Available

Get Fulcrum Therapeutics Inc. Data in Excel

Get Fulcrum Therapeutics Inc. Data in Excel